Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implications

Lung cancer is the leading cause of cancer mortality. Despite therapeutic advances in recent years, new treatment strategies are needed to improve outcomes of lung cancer patients. Mutant p53 is prevalent in lung cancers and drives several hallmarks of cancer through a gain-of-function oncogenic pro...

全面介绍

书目详细资料

Principais autores:	Eziafa I. Oduah, Susan T. Sharfstein, Nagashree Seetharamu, Steven R. Grossman, Larisa Litovchick
格式:	Artigo
语言:	Inglês
出版:	Frontiers Media S.A. 2024-04-01
丛编:	Frontiers in Oncology
主题:	NSCLC proteasome TP53 mutant p53 proteasome inhibitor
在线阅读:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1363543/full
标签:	添加标签 没有标签, 成为第一个标记此记录!